Skip to main content

Table 3 Meta-regression analysis for the associated factors and risk of PAD events in patients with SGLT2i treatment

From: SGLT2 inhibitors and lower limb complications: an updated meta‐analysis

Parameter β 95% CI P value Parameter β 95% CI P value
Demographic characteristic
 Age (year old) − 0.057 − 0.133, 0.018 0.133 Sex (male%) − 0.003 − 0.026, 0.019 0.780
 BMI (kg/m2) − 0.011 − 0.071, 0.050 0.720 Diabetes duration (year) − 0.001 − 0.104, 0.102 0.984
HbA1c and weight change
 HbA1c change (%) − 0.540 − 1.518, 0.437 0.269 Weight change (kg)* − 0.359 − 0.545, − 0.172 < 0.001
 HbA1c change difference (%) − 1.126 − 3.166, 0.914 0.269 Weight change difference (kg)* − 0.264 − 0.472, − 0.056 0.014
Hemodynamic indicator
 Baseline SBP (mmHg) 0.004 − 0.061, 0.070 0.896 Baseline DBP (mmHg) 0.017 − 0.338, 0.372 0.922
 SBP change (mmHg)* − 0.207 − 0.390, − 0.023 0.028 DBP change (mmHg) − 0.191 − 0.493, 0.110 0.201
 Hemoglobin change (g/L) − 0.076 − 0.746, 0.594 0.782 HCT change − 0.242 − 1.117, 0.634 0.552
 Volume depletion (event%) − 0.061 − 0.269, 0.147 0.528 Osmotic diuresis (event%) 0.367 − 0.091, 0.825 0.091
Renal function profile
 Baseline eGFR (mL/min/1.73m2) 0.019 − 0.014, 0.051 0.242 eGFR change (mL/min/1.73m2) − 0.184 − 0.473, 0.107 0.200
PAD risk factor
 Previous PAD (%) 0.017 − 0.039, 0.072 0.411
  1. *P < 0.05. BMI body mass index, SGLT2i sodium glucose co-transporter 2 inhibitor, PAD peripheral arterial disease, SBP systolic blood pressure, DBP diastolic blood pressure, HCT hematocrit, eGFR estimated glomerular filtration rate